2026 Colorado Infectious Diseases Symposium

8 Videos + Subtitles | Approximately 4 Hours 34 Minutes | CU Anschutz

Stay current with important and evolving topics in infectious disease practice with the 2026 Colorado Infectious Diseases Symposium, hosted by the University of Colorado Anschutz Medical Campus Department of Medicine, Division of Infectious Diseases.

Held on April 18, 2026, this focused infectious diseases program brings together physicians, infectious disease specialists, pharmacists, fellows, researchers, and other healthcare professionals for clinically relevant updates across antimicrobial therapy, vaccination, bloodstream infections, immunocompromised patients, HIV/global health, outpatient antimicrobial therapy, and cancer prevention.

The collection includes 8 video sessions with accompanying subtitle files, providing approximately 4 hours and 34 minutes of educational content.

Important Format Information

Included

• 8 Video Presentations
• Subtitle Files
• Approximately 4 Hours 34 Minutes of content

Not Included

• No PDFs
• No Presentation Slides
• No Handouts

This package is specifically provided as:

Videos + Subtitles Only

Do not purchase expecting PDF slides, syllabus files, or presentation handouts.

Course Details

• Course: 2026 Colorado Infectious Diseases Symposium
• Host: University of Colorado Anschutz Medical Campus
• Department: Department of Medicine
• Division: Division of Infectious Diseases
• Date: April 18, 2026
• Location: Aurora, Colorado
• Venue: Donald Elliman Conference Center, Anschutz Health Sciences Building
• Videos: 8
• Duration: Approximately 4 Hours 34 Minutes
• Format: Videos + Subtitles
• PDFs / Slides: Not Included
• Language: English
• Specialty: Infectious Diseases / Internal Medicine

Course Overview

Modern infectious disease practice is increasingly shaped by changes in:

• Vaccination policy
• Antimicrobial resistance
• New anti-infective therapies
• Antibiotic stewardship
• Bloodstream infection management
• Outpatient antimicrobial therapy
• Care transitions
• Immunocompromised populations
• HIV medicine
• Transplant infectious disease
• HPV-associated disease
• Global HIV programs

The 2026 Colorado Infectious Diseases Symposium provides focused expert discussions across these areas while emphasizing practical clinical decision-making.

The program combines traditional lectures with:

• Clinical case discussions
• Multidisciplinary panels
• Pharmacy perspectives
• Transition-of-care discussions
• Global infectious disease updates
• Interactive knowledge review

Who Should Take This Course?

This program is particularly relevant for:

• Infectious Disease Physicians
• Internal Medicine Physicians
• Hospitalists
• Infectious Disease Fellows
• Internal Medicine Residents
• Pharmacists
• Antimicrobial Stewardship Pharmacists
• Advanced Practice Practitioners
• Clinical Researchers
• Public Health Professionals
• HIV Specialists
• Transplant Medicine Clinicians
• Healthcare professionals interested in infectious diseases

2026 Colorado Infectious Diseases Symposium Curriculum

Video 1 – Current Era of Vaccinations in the United States

Edwin Asturias, MD

Professor of Pediatrics, Infectious Diseases
Director, Latin America Projects at the Colorado School of Public Health

This keynote session reviews the rapidly evolving landscape of vaccination in the United States.

Potentially relevant areas include:

• Current vaccination practice
• Vaccine recommendations
• Infectious disease prevention
• Vaccine implementation
• Population health
• Changing vaccine policy
• High-risk populations
• Clinical decision-making around immunization

Vaccination Updates in Infectious Disease Practice

Vaccination remains one of the most effective tools for prevention of infectious disease.

Clinicians must continually account for:

• Patient age
• Immunocompromised status
• Previous vaccination
• Comorbid disease
• Exposure risk
• Travel
• Occupational risk
• Evolving recommendations

The keynote provides an important update for clinicians navigating contemporary vaccine practice.

Video 2 – Oral Antibiotics for Staphylococcus aureus Bacteremia

Rebecca O’Toole, PharmD

PGY2 Infectious Diseases Pharmacy Resident
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

This session addresses an important and evolving clinical question:

Can selected patients with Staphylococcus aureus bacteremia transition to oral antimicrobial therapy?

Staphylococcus aureus Bacteremia

S. aureus bacteremia is associated with significant morbidity and requires careful evaluation.

Important clinical considerations include:

• Source identification
• Blood-culture clearance
• Endocarditis evaluation
• Metastatic infection
• Antibiotic selection
• Duration of therapy
• Source control
• Follow-up

IV-to-Oral Antibiotic Transition

Traditionally, prolonged intravenous therapy has been common for serious bloodstream infections.

Increasing clinical interest has focused on whether carefully selected patients may be candidates for an oral step-down strategy.

Considerations may include:

• Clinical stability
• Infection source
• Blood-culture clearance
• Organism susceptibility
• Oral bioavailability
• Adherence
• Presence or absence of complicated infection
• Follow-up reliability

This represents an important area of antimicrobial stewardship and contemporary infectious disease management.

Video 3 – New Pharmacologic Therapies in Infectious Diseases

Randolph V. Fugit, PharmD, BCPS

Clinical Associate Professor
University of Colorado Skaggs School of Pharmacy
Clinical Pharmacist & Director of Antimicrobial Stewardship Program
Rocky Mountain Regional VA Medical Center

This session reviews newer pharmacologic therapies relevant to infectious disease practice.

New Antimicrobials

The therapeutic landscape continues to evolve in response to:

• Antimicrobial resistance
• Difficult-to-treat pathogens
• Toxicity of existing therapies
• Drug interactions
• Changing susceptibility patterns
• Need for more convenient formulations

Clinicians need to understand not only whether a new antimicrobial is available, but:

Spectrum → Indication → Resistance → Pharmacology → Safety → Appropriate Patient

Antimicrobial Stewardship

New antimicrobial options should be incorporated responsibly.

Important principles include:

• Appropriate indication
• Culture-guided therapy
• De-escalation
• Duration optimization
• Resistance prevention
• Toxicity reduction
• Cost-conscious prescribing

Video 4 – Diagnostic & Treatment Dilemmas in Immunocompromised Populations

Fellow Cases

Jenn Chou, MD
Adult Infectious Diseases Fellow, CU Anschutz

Maria Gallanis, MD
Neuro-Infectious Diseases and Autoimmune Fellow, CU Anschutz

Moderators Include

Edward Gardner, MD

Professor of Medicine, Infectious Diseases
Director of ID Clinic & Center for Positive Health, Denver Health

Sarah Rowan, MD

Associate Professor of Medicine, Infectious Diseases
Director, Division of HIV/STI Prevention/Control, Public Health Institute at Denver Health

Steven Mudroch, MD

Assistant Professor of Medicine, Infectious Diseases
Associate Director, PrEP Clinical Program

Infectious Disease in Immunocompromised Patients

Immunocompromised patients can present with infections that are:

• Atypical
• Rapidly progressive
• Difficult to diagnose
• Resistant to conventional therapy
• Caused by opportunistic organisms
• Complicated by treatment interactions

The case-based format allows learners to work through complex diagnostic and therapeutic problems.

Diagnostic Challenges

Evaluation may require consideration of:

• Type of immune deficiency
• Immunosuppressive medications
• Transplant status
• HIV status
• Neutropenia
• Previous antimicrobial exposure
• Travel
• Environmental exposures
• Timing of symptoms
• Opportunistic pathogens

A standard infectious disease differential may not be sufficient in severely immunocompromised patients.

Treatment Challenges

Management decisions may be complicated by:

• Drug interactions
• Organ dysfunction
• Antimicrobial resistance
• Toxicity
• Immunosuppression
• Need for prolonged therapy
• Need for combination treatment
• Diagnostic uncertainty

The session emphasizes clinical reasoning in complex real-world scenarios.

Video 5 – HPV-Related Anal Cancer Screening & Prevention

Getting to the Bottom of Guideline Implementation

Hillary Dunlevy, MD

Associate Professor of Medicine, Infectious Diseases
Director of the Anal Dysplasia Clinic, University of Colorado Hospital

This session reviews an important intersection between:

Infectious Disease + HPV + Cancer Prevention

HPV & Anal Cancer

Persistent infection with oncogenic human papillomavirus can contribute to anal dysplasia and anal cancer.

Certain populations may have increased risk and may require more individualized screening strategies.

The session explores issues surrounding:

• HPV
• Anal dysplasia
• Anal cancer
• Screening
• Prevention
• Guideline implementation
• High-risk populations
• Clinical follow-up

Translating Guidelines Into Clinical Practice

Publishing recommendations does not automatically result in successful implementation.

Clinicians must consider:

• Who should be screened?
• When should screening begin?
• Which tests are appropriate?
• How should abnormal results be managed?
• Which patients require specialist evaluation?
• How should prevention strategies be integrated?

This session emphasizes the practical implementation of evolving guidance.

Video 6 – OPAT Transitions of Care Collaborative

Improving Care Across the Continuum

A roundtable discussion led by the Denver Health and Anschutz Medical Campus OPAT teams.

What Is OPAT?

OPAT – Outpatient Parenteral Antimicrobial Therapy allows selected patients to receive intravenous antimicrobial therapy outside the traditional inpatient setting.

Potential benefits can include:

• Earlier hospital discharge
• Reduced inpatient days
• Greater patient convenience
• Continuation of prolonged antimicrobial therapy outside the hospital

However, safe OPAT requires careful coordination.

OPAT Transitions of Care

The transition:

Hospital → Home / Skilled Facility / Outpatient Setting

can create risks related to:

• Antibiotic choice
• Dose
• Duration
• Venous access
• Laboratory monitoring
• Adverse effects
• Follow-up
• Communication
• Missed doses
• Readmission

The multidisciplinary discussion examines strategies for improving continuity across these transitions.

OPAT Team-Based Care

Effective OPAT programs may involve collaboration between:

• Infectious disease physicians
• Pharmacists
• Nurses
• Hospitalists
• Care coordinators
• Home infusion teams
• Primary care clinicians
• Patients and caregivers

This makes transition-of-care design particularly important.

Video 7 – PEPFAR: Then and Now

Lisa Abuogi, MD, MSc

Associate Professor of Pediatrics, Infectious Diseases & Center for Global Health
Colorado School of Public Health Department of Epidemiology

This session examines the evolution and impact of PEPFAR – the U.S. President’s Emergency Plan for AIDS Relief.

PEPFAR & Global HIV Care

PEPFAR has played a major role in the global response to HIV/AIDS.

The session places current HIV programs within the broader historical context of:

• HIV treatment expansion
• HIV prevention
• Global health systems
• International partnerships
• Antiretroviral therapy
• Maternal and child health
• Public health infrastructure

HIV Then & Now

The HIV epidemic and its treatment have changed dramatically over time.

Modern HIV care increasingly involves:

• Effective antiretroviral therapy
• Viral suppression
• Prevention
• PrEP
• Long-term health
• Comorbidity management
• Public health strategy

The PEPFAR session provides perspective on how international programs have contributed to these changes.

Video 8 – Infectious Diseases Trivia

Meghan Jeffres, PharmD

Associate Professor of Clinical Pharmacy
Clinical Pharmacist, Infectious Diseases
Vice Chair for Education, Infectious Disease Pharmacy

This interactive session uses an engaging knowledge-review format to reinforce key infectious disease concepts.

Rather than functioning as a traditional lecture, ID Trivia can help participants:

• Test clinical knowledge
• Recall high-yield infectious disease facts
• Identify knowledge gaps
• Reinforce pharmacology
• Review clinical decision-making
• Consolidate topics from the symposium

Major Topics Covered

The 2026 Colorado Infectious Diseases Symposium includes coverage of:

• Infectious Diseases
• Antimicrobial Therapy
• New Antibiotics
• Antimicrobial Stewardship
• Vaccination
• Vaccines in 2026
• Staphylococcus aureus
• S. aureus Bacteremia
• Oral Antibiotics
• IV-to-Oral Antibiotic Therapy
• Bloodstream Infections
• Immunocompromised Patients
• Opportunistic Infections
• Transplant Infectious Disease
• HIV
• PrEP
• HPV
• HPV-Related Anal Cancer
• Anal Dysplasia
• Cancer Screening
• OPAT
• Outpatient Parenteral Antimicrobial Therapy
• Transitions of Care
• PEPFAR
• Global Health
• Infectious Disease Pharmacology
• Clinical Infectious Disease Cases

Infectious Diseases Pharmacology

Pharmacists play a prominent educational role within this symposium.

The program includes content relevant to:

• New antimicrobials
• Antibiotic selection
• S. aureus bacteremia
• Oral antimicrobial therapy
• Stewardship
• Drug safety
• Optimizing antimicrobial use

This makes the program particularly relevant not only to physicians but also to infectious disease and antimicrobial stewardship pharmacists.

Immunocompromised Host Infections

A dedicated case-based session addresses one of the most challenging areas of infectious disease medicine.

Important clinical populations may include patients with:

• HIV
• Transplantation
• Immunosuppressive therapy
• Immune-mediated disease
• Complex comorbidities

These patients often require broader differential diagnoses and individualized antimicrobial strategies.

HPV-Related Disease & Cancer Prevention

HPV-related anal cancer screening represents an evolving area where infectious disease clinicians may contribute to:

• Risk identification
• Prevention
• Screening
• Guideline implementation
• HIV-associated care
• Referral pathways

This adds an important preventive-medicine component to the symposium.

OPAT & Antimicrobial Transitions of Care

OPAT has become an important part of modern infectious disease practice.

The symposium examines how healthcare teams can safely move patients from inpatient antimicrobial therapy to outpatient treatment while maintaining:

• Clinical monitoring
• Appropriate laboratory testing
• Medication safety
• Communication
• Follow-up
• Continuity of care

Vaccines & Prevention

The vaccination keynote provides a timely overview of contemporary immunization practice.

Vaccines remain important across:

• Routine adult health
• Pediatric health
• Immunocompromised populations
• Infectious disease prevention
• Public health
• Travel medicine
• High-risk populations

Global HIV & PEPFAR

The program also extends beyond U.S.-based clinical infectious disease practice.

The PEPFAR session provides a global perspective on:

• HIV treatment
• Prevention
• Public health
• International health systems
• Program development
• Evolution of the global HIV response

Why This Symposium Is Useful

One of the strengths of the 2026 Colorado Infectious Diseases Symposium is the diversity of its clinical content.

The program progresses through:

Vaccines → Bacteremia → New Antimicrobials → Immunocompromised Hosts → HPV Prevention → OPAT → Global HIV → Knowledge Review

This provides a compact update across several important infectious disease areas rather than concentrating on a single disease.

Learners can use the collection to:

• Review current vaccination issues
• Improve antimicrobial decision-making
• Review S. aureus bacteremia management
• Explore oral antibiotic strategies
• Learn about newer anti-infective therapies
• Improve clinical reasoning in immunocompromised patients
• Review HPV-associated anal cancer prevention
• Strengthen OPAT transition-of-care knowledge
• Review PEPFAR and global HIV
• Reinforce key infectious disease concepts

Target Audience

The program is particularly useful for:

• Infectious Disease Physicians
• Internists
• Hospitalists
• Infectious Disease Fellows
• Internal Medicine Residents
• Pharmacists
• Antimicrobial Stewardship Specialists
• Advanced Practice Practitioners
• Clinical Researchers
• Public Health Professionals
• HIV Specialists
• Transplant Clinicians
• Healthcare Professionals with an interest in Infectious Diseases

Product / Delivery Information

• Product: 2026 Colorado Infectious Diseases Symposium
• Provider: University of Colorado Anschutz Medical Campus
• Department: Department of Medicine
• Division: Infectious Diseases
• Date: April 18, 2026
• Videos: 8
• Duration: Approximately 4 Hours 34 Minutes
• Format: Videos + Subtitles
• PDFs: Not Included
• Slides: Not Included
• Language: English

Important Format Notice

This package contains videos and subtitle files only.

It does not include:

• PDF lecture slides
• Presentation files
• Handouts
• Syllabus PDFs

Customers specifically requiring presentation slides should take this limitation into account before purchasing.

CME / Certificate Notice

The official Colorado Infectious Diseases Symposium was hosted through the University of Colorado Anschutz School of Medicine, which is accredited by the ACCME to provide continuing medical education for physicians.

However, ownership of independently delivered video and subtitle files should not be advertised as including official CU Anschutz CME credit or a certificate unless official participation and credit-claiming access are explicitly included.

4. Short Description

2026 Colorado Infectious Diseases Symposium from CU Anschutz provides 8 expert-led video sessions with subtitles covering important updates in contemporary infectious disease practice.

Topics include vaccination, oral antibiotics for Staphylococcus aureus bacteremia, new antimicrobial therapies, diagnostic and treatment dilemmas in immunocompromised patients, HPV-related anal cancer screening, OPAT transitions of care, PEPFAR, HIV/global health, and infectious disease clinical review.

Videos: 8
Duration: Approximately 4 Hours 34 Minutes
Format: Videos + Subtitles
PDFs / Slides: Not Included
Date: April 18, 2026

Ideal for infectious disease physicians, internists, hospitalists, fellows, residents, pharmacists, and other healthcare professionals.

Course Content

1. Fellow Cases: Diagnostic and Treatment Dilemmas in Immunocompromised Populations – Case 1

Jenn Chou — 28:40

2. Fellow Cases: Diagnostic and Treatment Dilemmas in Immunocompromised Populations – Case 2

Maria Gallanis — 24:35

3. New Antimicrobials in 2026: Something Old, Something New, Something Borrowed, Something Blue

Randolph Fugit — 36:44

4. PEPFAR: Then and Now

Lisa Abuogi — 32:45

5. OPAT Transitions of Care Collaborative: Improving Care Across the Continuum

Julianne Randlemon, Whitney Miller, Larissa Pisney, Lorna Allen & Marisa Brightman — 24:45

6. HPV-Related Anal Cancer Screening and Prevention – Getting to the Bottom of Guideline Implementation

Hillary Dunlevy — 39:16

7. Current Era of Vaccinations in the United States

Edwin Asturias — 46:20

8. Oral Antibiotics for Staphylococcus aureus Bacteremia

Rebecca O’Toole — 30:06

---

Key Topics

• New Antimicrobials in 2026
• Infectious Diseases in Immunocompromised Patients
• Diagnostic & Treatment Dilemmas
• Current Vaccination Updates
• Oral Antibiotics for Staphylococcus aureus Bacteremia
• OPAT & Transitions of Care
• HPV-Related Anal Cancer Screening & Prevention
• PEPFAR Updates
• Contemporary Infectious Disease Management

Target Audience

Recommended for:

• Infectious Disease Physicians
• Internal Medicine Physicians
• Hospitalists
• Infectious Disease Fellows
• Residents
• Pharmacists
• Advanced Practice Providers
• Healthcare Professionals interested in Infectious Diseases